These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354 [TBL] [Abstract][Full Text] [Related]
7. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? Feagan BG; Sandborn WJ Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239 [TBL] [Abstract][Full Text] [Related]
8. [Regional enterocolitis--a problem rich disease picture in diagnosis and therapy]. Schröder H; Petrat H Zentralbl Chir; 1985; 110(9):564-71. PubMed ID: 2409710 [TBL] [Abstract][Full Text] [Related]
9. Can postoperative relapse of Crohn's disease be prevented? Dumois RA; Herrera JL Am J Gastroenterol; 2001 Jan; 96(1):249. PubMed ID: 11197264 [No Abstract] [Full Text] [Related]
10. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504 [TBL] [Abstract][Full Text] [Related]
11. Quality of life improves within 30 days of surgery for Crohn's disease. Delaney CP; Kiran RP; Senagore AJ; O'Brien-Ermlich B; Church J; Hull TL; Remzi FH; Fazio VW J Am Coll Surg; 2003 May; 196(5):714-21. PubMed ID: 12742203 [TBL] [Abstract][Full Text] [Related]
12. [Azathioprine for prevention of postoperative recurrence in Crohn's disease]. Abdelli MN; Ben Abdallah H; Houissa F; Bouali MR; Khediri MF Tunis Med; 2007 Jul; 85(7):569-72. PubMed ID: 18064988 [TBL] [Abstract][Full Text] [Related]
15. [Recurrence of Crohn's disease after surgery--causes and risks]. Mirow L; Hauenschild L; Hildebrand P; Kleemann M; Keller R; Franke C; Roblick UJ; Bruch HP; Kujath P Zentralbl Chir; 2008 Apr; 133(2):182-7. PubMed ID: 18415909 [TBL] [Abstract][Full Text] [Related]
16. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Sandborn WJ; Feagan BG; Lichtenstein GR Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506 [TBL] [Abstract][Full Text] [Related]
17. [Crohn disease: prognostic factors and therapeutic choices]. Roseano M; Turoldo A; Ziza F; Balani A; Scaramucci M Chir Ital; 2002; 54(2):141-54. PubMed ID: 12038104 [TBL] [Abstract][Full Text] [Related]
18. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties. Tromm A; Griga T; May B Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173 [TBL] [Abstract][Full Text] [Related]
19. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Teml A; Kratzer V; Schneider B; Lochs H; Norman GL; Gangl A; Vogelsang H; Reinisch W Am J Gastroenterol; 2003 Oct; 98(10):2226-31. PubMed ID: 14572572 [TBL] [Abstract][Full Text] [Related]
20. Surgical intervention for neonatal and infantile-onset severe colonic Crohn's disease: report of three cases. Uchida K; Miki C; Inoue M; Otake K; Yoshiyama S; Araki T; Watanabe H; Okita Y; Kusunoki M Dis Colon Rectum; 2008 Feb; 51(2):247-50. PubMed ID: 18175185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]